Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

9.8K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The economic burden of dementia in Europe: COIN-Eu dementia.

Journal of Alzheimer's disease : JAD·2026
Same author

Neurosarcoidosis as an elusive mimicker of infection and neoplasia: a case report.

Journal of neurology·2026
Same author

Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.

Journal of neurology·2026
Same author

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.

Nature medicine·2026
Same author

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026

Related Experiment Video

Updated: Sep 9, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.6K

Stool Glial Fibrillary Acidic Protein Is Elevated in Progressive Multiple Sclerosis.

Luke A Schwerdtfeger1, Federico Montini1,2, Martina Antonini Cencicchio2

  • 1Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Neurology(R) Neuroimmunology & Neuroinflammation
|August 28, 2025
PubMed
Summary

Higher levels of stool glial fibrillary acidic protein (GFAP) are found in progressive multiple sclerosis (MS) patients, suggesting it may be a prognostic biomarker for disease worsening.

More Related Videos

Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis
09:36

Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis

Published on: June 23, 2022

3.6K
Bioluminescence Imaging of Neuroinflammation in Transgenic Mice After Peripheral Inoculation of Alpha-Synuclein Fibrils
09:32

Bioluminescence Imaging of Neuroinflammation in Transgenic Mice After Peripheral Inoculation of Alpha-Synuclein Fibrils

Published on: April 13, 2017

8.7K

Related Experiment Videos

Last Updated: Sep 9, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.6K
Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis
09:36

Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis

Published on: June 23, 2022

3.6K
Bioluminescence Imaging of Neuroinflammation in Transgenic Mice After Peripheral Inoculation of Alpha-Synuclein Fibrils
09:32

Bioluminescence Imaging of Neuroinflammation in Transgenic Mice After Peripheral Inoculation of Alpha-Synuclein Fibrils

Published on: April 13, 2017

8.7K

Area of Science:

  • Neuroimmunology
  • Gastroenterology
  • Microbiome research

Background:

  • Multiple sclerosis (MS) is linked to gut microbiota and intestinal changes.
  • Enteric glial cells, expressing GFAP and S100β, influence gut nervous and immune systems.
  • Current serum markers like GFAP and neurofilament light chain predict worsening but don't distinguish MS subtypes.

Purpose of the Study:

  • To investigate enteric glial cell function in MS.
  • To assess stool GFAP (st-GFAP) as a potential biomarker differentiating MS disease courses.

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) measured st-GFAP in healthy controls (HCs), relapsing-remitting MS (RRMS), and progressive MS (ProgMS) patients.
  • Clinical follow-up at 2 and 5 years assessed disease progression.
  • Enteric glial hyperplasia was examined via GFAP and S100β immunoreactivity in colonic and duodenal tissue.

Main Results:

  • st-GFAP levels were significantly higher in ProgMS compared to RRMS and HCs.
  • st-GFAP correlated positively with baseline and longitudinal Expanded Disability Status Scale (EDSS) scores and 25-foot walk time.
  • Enteric glial hyperplasia was observed in a primary progressive MS patient's colonic mucosa.
  • st-GFAP showed a negative association with *Eubacterium hallii* in ProgMS patients.

Conclusions:

  • Exploratory findings suggest an altered enteric glial phenotype in progressive MS.
  • st-GFAP may serve as a prognostic biomarker for MS disease progression.